|
|
|
本文已被:浏览 654次 下载 416次 |
码上扫一扫! |
|
基于脂质代谢组学研究羟基红花黄色素A治疗高脂血症LDLR-/-小鼠的作用机制 |
唐华靖1, 罗雅歌1, 杨磊2, 徐宝欣2, 徐静雅2, 苗琳1, 柴丽娟1, 张晗1, 王怡1, 毛浩萍1
|
1.天津中医药大学方剂学教育部重点实验室, 天津 301617;2.悦康药业集团股份有限公司, 北京 100176
|
|
摘要: |
[目的] 基于脂质代谢组学方法考察羟基红花黄色素A(HSYA)对高脂饲料诱导的LDLR-/-小鼠高脂血症脂质代谢的影响及其机制。[方法] 将28只雄性LDLR-/-小鼠分为对照组与高脂组。对照组喂养普通饲料,高脂组喂养高脂饲料,6周后,高脂组按照血清中低密度脂蛋白胆固醇(LDL-C)含量平均分为4组:模型组、辛伐他汀组、HSYA(3.8 mg/kg)低剂量组、HSYA(7.6 mg/kg)高剂量组。给药11周,给药期间同时给予高脂饲料饲养。全自动生化仪检测小鼠血清中丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、三酰甘油(TG)、总胆固醇(TC)、LDL-C含量,苏木精-伊红(HE)染色观察肝组织病理形态,油红O染色观察小鼠肝脏组织脂肪蓄积情况,采用靶向脂质组学技术对LDLR-/-小鼠血清中脂质进行测定。[结果] 与对照组比较,模型组小鼠血清中LDL-C、TC、TG、AST、ALT含量升高(P<0.05),肝组织出现大小不等的脂滴浸润,肝细胞排列紊乱,大量脂质蓄积。与模型组比较,HSYA两组小鼠血清中LDL-C、TC、TG、AST、ALT含量降低(P<0.05),肝脏的脂肪变性、脂质蓄积等病理情况得到改善。脂质组学检测结果显示,模型组和对照组之间具有差异的脂质分子共有14种(VIP>1,P<0.05)。HSYA两组与模型组比较,17种脂质分子呈现相反的趋势并具有差异,分别为PE(18∶0/18∶1)、PE(18∶0/18∶2)、PE(18∶0/20∶3)、PE(18∶0/20∶4)、PE(O-18∶0/18∶1)、PE(O-18∶0/20∶4)、LPE(18∶1)、LPE(20∶4)、FFA(22∶4)、PI(18∶0/18∶2)、PI(16∶0/18∶1)、PI(18∶1/18∶1)、LPI(18∶0)、PG(18∶1/16∶1)、PG(18∶1/18∶1)、PG(18∶1/18∶2)、PA(18∶1/18∶1)(VIP>1,P<0.05)。[结论] 研究利用脂质组学技术,发现HSYA可以通过调节高脂血症LDLR-/-小鼠血清中脂质代谢水平,发挥治疗高脂血症的作用,为临床应用HSYA提供了新的参考依据。 |
关键词: 羟基红花黄色素A 高脂血症 脂质组学 脂代谢 |
DOI:10.11656/j.issn.1673-9043.2024.01.01 |
分类号:R589.2 |
基金项目: |
|
To investigate the mechanism of Hydroxysafflor yellow A in the treatment of hyperlipidemia in LDLR-/- mice based on lipid metabolomics |
TANG Huajing1, LUO Yage1, YANG Lei2, XU Baoxin2, XU Jingya2, MIAO Lin1, CHAI Lijuan1, ZHANG Han1, WANG Yi1, MAO Haoping1
|
1.Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China;2.Youcare Pharmaceutical Group Co., Ltd., Beijing 100176, China
|
Abstract: |
[Objective] To investigate the effect and mechanism of Hydroxysafflor yellow A(HSYA) on lipid metabolism in LDLR-/- mice with hyperlipidemia induced by high-fat diet based on lipid metabolomics. [Methods] Twenty-eight male LDLR-/- mice were divided into control group and high-fat diet group. The control group was fed with normal diet, and the high-fat group was fed with high-fat diet. After 6 weeks, according to the content of LDL-C, the mice were divided into four groups[model group, simvastatin group, low dose HSYA(3.8 mg/kg) and high dose HSYA(7.6 mg/kg)]. The drug was administered for 11 weeks, and high-fat diet was given simultaneously during the drug administration. The content of alanine aminotransferase(ALT), aspartate aminotransferase(AST), triglyceride(TG), total cholesterol(TC), and low-density lipoprotein cholesterol(LDL-C) in serum of mice were detected by automatic biochemical instrument, the pathological morphology of liver histology was observed by hematoxylin-eosin staining, and the fat deposition of liver tissues of mice was observed by oil red O staining, and lipids in the serum of LDLR-/- mice were measured by targeted lipidomic technology. [Results] Compared with the control group, the serum content of LDL-C, TC, TG, AST and ALT in the model group were increased(P<0.05). The liver tissue showed infiltration of lipid droplets of different sizes, disorderly arrangement of hepatocytes, and a large number of lipid deposits. Compared with the model group, the serum content of LDL-C, TC, TG, AST and ALT in the HSYA group were decreased(P<0.05), liver steatosis, lipid deposition and other pathological conditions were improved. The results of lipid profiling showed that there were 14 different lipid molecules(VIP>1, P<0.05). Compared with the model group, 17 lipid molecules in the HSYA group showed the opposite trend and had differences, Respectively PE(18:0/18:1), PE(18:0/18:2), PE(18:0/20:3), PE(18:0/20:4), PE(O-18:0/18:1), PE(O-18:0/20:4), LPE(18:1), LPE(20:4), FFA(22:4), PI(18:0/18:2), PI(16:0/18:1), PI(18:1/18:1), LPI(18:0), PG(18:1/16:1), PG(18:1/18:1), PG(18:1/18:2), PA(18:1/18:1)(VIP>1, P<0.05). [Conclusion] Using lipidomics technology, this study found that HSYA could play a role in the treatment of hyperlipidemia by regulating lipid metabolism in the serum of hyperlipidemia LDLR-/- mice, and provided a new reference for its clinical application. |
Key words: Hydroxysafflor yellow A hyperlipidemia lipidomics metabolism of lipid |
|
|
|
|